Autobahn Therapeutics, Inc. announced that it has raised $32.7 million in a round of funding on September 8, 2022. The Transaction included participation from GT Healthcare Capital Partners, returning investors Arch Venture Partners, L.P., The Invus Group, LLC, Bristol-Myers Squibb Company,Biogen Inc., BVF Partners L.P., Pfizer Venture Investments LLC, Alexandria Venture Investments, LLC, Section 32, LLC, Samsara BioCapital LLC and CHI Advisors LLC.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.77 USD | -8.37% | -6.92% | -12.38% |
05:04pm | Stocks in motion: Large caps struggle | |
04:39pm | Trending : Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.38% | 99.03B | |
+24.17% | 562B | |
-6.46% | 358B | |
+18.40% | 322B | |
+7.29% | 297B | |
+13.60% | 219B | |
+6.06% | 199B | |
-10.43% | 196B | |
-11.29% | 149B | |
-7.09% | 146B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Autobahn Therapeutics, Inc. announced that it has received $32.7 million in funding from a group of investors